For research use only. Not for therapeutic Use.
PF-5190457 (CAT: I008714) is an orally available and potent ghrelin receptor inverse agonist. It exhibits high selectivity for the ghrelin receptor and acts as an antagonist, effectively blocking the activity of ghrelin, a hormone involved in appetite regulation and energy balance. By inhibiting ghrelin signaling, PF-5190457 has the potential to modulate metabolic processes and has shown promising effects in increasing insulin secretion in glucose-stimulated human islets. The compound has also demonstrated favorable pharmacological and safety profiles, leading to its advancement into human clinical trials. PF-5190457 represents a promising candidate for the treatment of metabolic disorders and further research in this area.
| Catalog Number | I008714 |
| CAS Number | 1334782-79-4 |
| Synonyms | PF-5190457; PF 5190457; PF5190457; PF-05190457; PF05190457; PF 05190457.;(R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethan-1-one |
| Molecular Formula | C29H32N6OS |
| Purity | ≥95% |
| Target | GHSR |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 2-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-[2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone |
| InChI | InChI=1S/C29H32N6OS/c1-19-11-25(31-18-30-19)22-3-5-24-21(12-22)4-6-26(24)35-16-29(17-35)7-9-33(10-8-29)27(36)13-23-15-34-14-20(2)37-28(34)32-23/h3,5,11-12,14-15,18,26H,4,6-10,13,16-17H2,1-2H3/t26-/m1/s1 |
| InChIKey | ZIUDADZJCKGWKR-AREMUKBSSA-N |
| SMILES | CC1=NC=NC(=C1)C2=CC3=C(C=C2)C(CC3)N4CC5(C4)CCN(CC5)C(=O)CC6=CN7C=C(SC7=N6)C |
| Reference | <br /> |
